Baidu
map

Head & Neck:幽门螺杆菌或增加喉癌风险

2015-09-21 佚名 生物谷

近日,根据8月28日在线发表在Head & Neck杂志上的一篇文章表明,研究发现幽门螺杆菌(H. pylori)感染可增加喉鳞状细胞癌的发生机率,但研究发现幽门螺杆菌(H. pylori)感染对鼻咽癌基本无影响。中国复旦大学医学院Zhou Jian 博士和他的同事们对幽门螺杆菌的感染作用进行了一项系统回顾性相关研究,本次回顾性研究旨在研究有关咽喉癌患者中幽门螺杆菌的感染情况。通过一系列整

近日,根据8月28日在线发表在Head & Neck杂志上的一篇文章表明,研究发现幽门螺杆菌(H. pylori)感染可增加喉鳞状细胞癌的发生机率,但研究发现幽门螺杆菌(H. pylori)感染对鼻咽癌基本无影响。

中国复旦大学医学院Zhou Jian 博士和他的同事们对幽门螺杆菌的感染作用进行了一项系统回顾性相关研究,本次回顾性研究旨在研究有关咽喉癌患者中幽门螺杆菌的感染情况。通过一系列整理分析,本次分析所得数据一共来自11项相关研究的结果,最后,研究人员应用该数据进行了meta分析。

在本项研究中研究人员发现,在研究幽门螺杆菌感染的过程中,最终得出的实验结果发现,与正常对照组相比,实验组中幽门螺杆菌含量有明显升高迹象,(比值比为2.87;95%置信区间内1.71比4.84;P < 0.0001)。喉鳞状细胞癌和鼻咽癌的比值比分别为3.28(95%置信区间,1.91比5.63;P < 0.0001)和1.35(95%置信区间,0.86比2.12;P = 0.188)。

“这个meta分析结果有力的证明了有关幽门螺旋杆菌感染与咽喉癌之间存在联系,特别是通过聚合酶链反应(PCR)和酶联免疫吸附试验(ELISA)进行确证后。”作者写道。“然而,通过分析发现幽门螺旋杆菌感染和鼻咽癌之间没有发现明显的关联迹象。此外,少量参与这项研究的项目在这个评估中引起了较大的置信区间。”

原文出处:

Jian Zhou PhD, Duo Zhang PhD, Yue Yang MD,et al.Association between helicobacter pylori infection and carcinoma of the larynx or pharynx.Head & Neck.2015


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=96293, encodeId=3eb29629303, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Aug 06 08:42:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811691, encodeId=2b8e1811691e7, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Aug 04 13:15:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061477, encodeId=d71b20614e7a1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 20 04:15:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043856, encodeId=b58c2043856e3, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Apr 24 00:15:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50443, encodeId=e58350443e9, content=拼了, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:00:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360781, encodeId=1b031360e81f0, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 23 02:15:00 CST 2015, time=2015-09-23, status=1, ipAttribution=)]
    2016-08-06 刘煜

    谢谢!学习了。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=96293, encodeId=3eb29629303, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Aug 06 08:42:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811691, encodeId=2b8e1811691e7, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Aug 04 13:15:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061477, encodeId=d71b20614e7a1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 20 04:15:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043856, encodeId=b58c2043856e3, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Apr 24 00:15:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50443, encodeId=e58350443e9, content=拼了, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:00:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360781, encodeId=1b031360e81f0, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 23 02:15:00 CST 2015, time=2015-09-23, status=1, ipAttribution=)]
    2016-08-04 kcb069
  3. [GetPortalCommentsPageByObjectIdResponse(id=96293, encodeId=3eb29629303, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Aug 06 08:42:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811691, encodeId=2b8e1811691e7, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Aug 04 13:15:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061477, encodeId=d71b20614e7a1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 20 04:15:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043856, encodeId=b58c2043856e3, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Apr 24 00:15:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50443, encodeId=e58350443e9, content=拼了, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:00:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360781, encodeId=1b031360e81f0, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 23 02:15:00 CST 2015, time=2015-09-23, status=1, ipAttribution=)]
    2016-01-20 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=96293, encodeId=3eb29629303, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Aug 06 08:42:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811691, encodeId=2b8e1811691e7, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Aug 04 13:15:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061477, encodeId=d71b20614e7a1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 20 04:15:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043856, encodeId=b58c2043856e3, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Apr 24 00:15:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50443, encodeId=e58350443e9, content=拼了, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:00:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360781, encodeId=1b031360e81f0, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 23 02:15:00 CST 2015, time=2015-09-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=96293, encodeId=3eb29629303, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Aug 06 08:42:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811691, encodeId=2b8e1811691e7, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Aug 04 13:15:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061477, encodeId=d71b20614e7a1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 20 04:15:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043856, encodeId=b58c2043856e3, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Apr 24 00:15:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50443, encodeId=e58350443e9, content=拼了, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:00:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360781, encodeId=1b031360e81f0, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 23 02:15:00 CST 2015, time=2015-09-23, status=1, ipAttribution=)]
    2015-12-30 xyfg98

    拼了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=96293, encodeId=3eb29629303, content=谢谢!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Aug 06 08:42:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811691, encodeId=2b8e1811691e7, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Aug 04 13:15:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061477, encodeId=d71b20614e7a1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 20 04:15:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043856, encodeId=b58c2043856e3, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Apr 24 00:15:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50443, encodeId=e58350443e9, content=拼了, beContent=null, objectType=article, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Wed Dec 30 13:00:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360781, encodeId=1b031360e81f0, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Sep 23 02:15:00 CST 2015, time=2015-09-23, status=1, ipAttribution=)]

相关资讯

1类新药幽门螺杆菌疫苗申报临床

国家食药监总局(CFDA)网站信息显示,中国人民解放军军事医学科学院生物工程研究所1类新药口服幽门螺杆菌基因工程活菌载体苗临床申报获受理。值得一提的是,岳阳兴长同类药品“口服重组幽门螺杆菌疫苗”在2009年已获批新药证书,但目前尚未实现产业化。幽门螺杆菌可引发慢性胃炎、胃溃疡、十二指肠溃疡、胃粘膜相关淋巴瘤等多种上消化道疾病。1994年WHO已确认其与胃癌发生密切相关,并将其列为一类致癌因子。据有

Cochrane DB Syst Rev:根除幽门螺杆菌可有效减小胃癌的发生危险

最新研究显示使用短程药物根除最为常见的幽门螺杆菌可降低胃癌的发生风险,该研究成果在线发表于 Cochrane Database of Systematic Reviews 。幽门螺杆菌存在三分之二的人群中,是胃溃疡发生的主要原因,但是多数人并没有自觉症状。“该次系统性回顾的发现再次为越来越多认为根除幽门螺杆菌可预防普通人群胃癌的发生这一观点提供了证据,”该研究的共同作者 Dr. Paul Moay

BMJ:幽门螺杆菌多种治疗方法比较

该研究的目的是确定最有效的根除幽门螺杆菌的治疗方案,以消除之前推荐的和较新的治疗方案中一些常见不良反应的可能性。该系统回顾与网络分析数据来源于PubMed,EMBASE数据库和Cochrane图书馆,没有语言或日期限制。研究人员选择了那些根除治疗成人中幽门螺旋杆菌方法具有全文报道的随机对照试验。研究人员确定了15565项研究,143项研究符合条件并包括在本次研究中。14种治疗方法的数据可用。研究人

J Cell Biol:樊代明院士发现miR-7可抑制胃癌的发展

据发表于Cell Biology 的一项研究表明,Cell Biology miR-7可通过抑制一个关键的信号通道以抑制胃癌的发生,而且这种保护机制可被致癌细菌幽门螺杆菌所损害。因此,发现能够诱导miR-7的药物可因此成为抑制胃癌发展的一项有效的治疗手段。据美国国立卫生研究院称,胃癌是全球第四大常见的癌症,且是癌症相关死亡的第三大原因。常在胃癌中表达降低的miR-7可通过抑制特定生长因子受体(IG

左氧氟沙星和含铋剂四联疗法作为幽门螺杆菌二线疗法安全有效

2015年4月,发表于《Aliment Pharmacol Ther.》的一篇文章介绍了一项考察:标准三联或非含铋剂四联疗法治疗失败后,使用左氧氟沙星和含铋剂四联疗法的幽门螺杆菌二线疗法的疗效和耐受性的前瞻性多中心研究。结果显示,该四联疗法简单、安全、有效。背景:最常用的二线根除幽门螺杆菌的方案是含铋剂四联治疗和含左氧氟沙星三联疗法,两者都提供了理想的结果。结合使用铋剂和左氧氟沙星可能会增强治疗方

Baidu
map
Baidu
map
Baidu
map